Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring GW695634G, GW695634X, GW678248X, pharmacokinetics, NNRTI, HIV
Eligibility Criteria
Inclusion criteria: CD4 cell count greater than or equal to 200 cells/mm3. HIV-1 RNA >2000 copies/mL. Must have history of NNRTI treatment with subsequent failure and documented evidence of an NNRTI-associated mutation or a phenotype displaying reduced activity to efavirenz, nevirapine or delavirdine. Normal resting 12-lead electrocardiogram. Exclusion criteria: Any history of seizure, CNS toxoplasmosis infection, or any CNS (central nervous system) lesion. Chronic diarrhea (>3 loose stools/day). An active CDC Category C disease (1993), except cutaneous Kaposi's Sarcoma (KS) not requiring systemic therapy during the trial. Less than 4 weeks since stopping anti-retroviral therapy (ART) therapy prior to Day 1. Any acute laboratory abnormality. Positive for HCV antibody or HepBsAG. Active infections requiring therapy in the previous 4 weeks.
Sites / Locations
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center
- GSK Clinical Trials Call Center